Related Experiment Video
Updated: Jun 12, 2025

Colon Ascendens Stent Peritonitis CASP - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 18, 2010
Aztreonam-avibactam for the treatment of intra-abdominal infections
Hannah Delp1, Gabrielle A Gibson1, Sara A Buckman2
1Pharmacy Department, Barnes-Jewish Hospital Plaza, St Louis, MO, USA.
Introduction:
Intra-abdominal infections are becoming increasingly common and can lead to significant morbidity and mortality. The incidence of these infections due to resistant gram-negative organisms is also increasing. Given this resistance, new antibiotic combinations are being developed, often utilizing older antibiotics and newer β-lactamase inhibitors. Aztreonam/avibactam (ATM-AVI) is one of the combination antibiotics, which combines aztreonam, a monobactam, with avibactam, a broad-spectrum β-lactamase inhibitor for the treatment of complicated intra-abdominal infections in combination with metronidazole.
Areas Covered:
In this drug evaluation manuscript, we provide an overview of intra-abdominal infections and an overview of currently available antimicrobial agents used to treat these infections. ATM-AVI is introduced, including chemistry, pharmacodynamics, pharmacokinetics and clinical studies of this compound.
Expert Opinion:
There are limited treatment options for complicated intra-abdominal infections due to resistant gram-negative organisms, especially those with metallo-β-lactamases. One treatment option for these infections is ATM-AVI, which was recently approved in Europe, in addition to metronidazole. These bacteria are difficult to treat, and this new compound is a safe and effective option for empiric treatment in places with a high incidence of infections due to these bacteria, and also treatment for infections when these resistant bacteria are isolated in culture.
Insights
Aztreonam/avibactam (ATM-AVI) offers a new treatment for complicated intra-abdominal infections. This combination antibiotic effectively combats resistant gram-negative organisms, addressing a critical unmet need in patient care.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Intra-abdominal infections (IAIs) are increasingly prevalent, associated with significant morbidity and mortality.
- Rising incidence of IAIs caused by antibiotic-resistant gram-negative organisms poses a therapeutic challenge.
- Limited treatment options exist for IAIs caused by resistant gram-negative pathogens, particularly those with metallo-β-lactamases.
Purpose of the Study:
- To evaluate aztreonam/avibactam (ATM-AVI) as a novel therapeutic option for complicated intra-abdominal infections.
- To review the chemistry, pharmacodynamics, pharmacokinetics, and clinical data of ATM-AVI.
- To discuss the role of ATM-AVI in managing infections caused by resistant gram-negative bacteria.
Main Methods:
- Drug evaluation manuscript synthesizing existing data.
- Review of antimicrobial agents for IAIs.
- Analysis of clinical studies on ATM-AVI.
Main Results:
- Aztreonam/avibactam (ATM-AVI) is a combination of aztreonam and avibactam, a broad-spectrum β-lactamase inhibitor.
- ATM-AVI, in combination with metronidazole, is approved in Europe for complicated IAIs.
- Demonstrated safety and efficacy for empiric treatment and targeted therapy against resistant gram-negative organisms.
Conclusions:
- ATM-AVI represents a valuable addition to the therapeutic armamentarium against complicated IAIs.
- It provides a crucial option for infections involving difficult-to-treat resistant gram-negative bacteria.
- Recommended for empiric use in high-incidence areas and for culture-confirmed resistant infections.
More Related Videos
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
14:52Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy
Published on: April 8, 2018
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Kidney Transplant II: Surgical Procedure
Aneurysm IV: Nursing Management
Acute Pyelonephritis I: Introduction